PLSE
PLSE
US74587B1017
Pulse Biosciences, Inc
Loading chart...

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Latest News

Related stocks

MMED
MMED • United States
MiniMed Group, Inc.
19.71 USD
5.55B USD
WRBY
WRBY • United States
Warby Parker Inc.
25.3 USD
3.13B USD 1Y +1.4%
ATRC
ATRC • United States
AtriCure, Inc.
55.81 USD
2.84B USD 1Y +50.6%
KMTS
KMTS • United States
Kestra Medical Technologies, Lt
26.98 USD
1.61B USD 1Y +7.4%
AZTA
AZTA • United States
Azenta, Inc.
37.72 USD
1.65B USD 1Y +11.7%
NVST
NVST • United States
Envista Holdings Corporation
23 USD
3.69B USD 1Y +10.4%
BLFS
BLFS • United States
BioLife Solutions, Inc.
38.61 USD
1.89B USD
ICUI
ICUI • United States
ICU Medical, Inc.
160.32 USD
4.01B USD 1Y +30.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
97.4% p.a.
Max Drawdown (5Y)
-95.0%
Sharpe Ratio (5Y)
0.18
Beta Factor
1.57
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 1.57 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (97.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -97.2% in the extended horizon.
ende